文献速递垂体与肾上腺疾病

原发性醛固酮增多症患者的生活质量:肾上腺切除术与药物治疗的比较效果研究

Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

本研究为SPARTACUS试验的事后比较效果研究,纳入184例原发性醛固酮增多症患者,比较肾上腺切除术与盐皮质激素受体拮抗剂对生活质量的影响。结果显示两种治疗均改善生活质量,但疑似醛固酮瘤患者术后生活质量改善优于疑似双侧肾上腺增生患者的药物治疗,术后1年多数生活质量指标恢复正常。

要点

  • 原发性醛固酮增多症患者基线生活质量低于一般人群,女性尤为明显。
  • 肾上腺切除术在多个生活质量维度上的改善优于盐皮质激素受体拮抗剂治疗。
  • 术后1年多数生活质量指标恢复至一般人群水平,药物治疗组多数改善但未全部达标。

核心结论

  • 两种治疗均改善原发性醛固酮增多症患者的生活质量,凸显识别此类患者的重要性。
  • 疑似醛固酮瘤患者行肾上腺切除术后生活质量改善程度大于疑似双侧肾上腺增生患者启动药物治疗。

研究设计与样本

  • SPARTACUS试验内的事后比较效果研究。
  • 纳入原发性醛固酮增多症患者184例。
  • 干预为肾上腺切除术或盐皮质激素受体拮抗剂。
  • 在基线、6个月和1年随访时采用RAND SF-36和EQ-5D问卷评估生活质量。
  • 研究设置包括12家荷兰医院和1家波兰医院。

主要发现

  • 基线时,原发性醛固酮增多症患者在8个RAND SF-36子量表中的7个、两个汇总评分、5个EQ-5D维度中的3个及视觉模拟评分均低于一般人群,女性尤为明显。
  • 肾上腺切除术在7个RAND SF-36子量表、两个汇总评分及健康变化方面的有益效应大于盐皮质激素受体拮抗剂。
  • EQ-5D方面,肾上腺切除术在2个维度和视觉模拟评分上显示优势。
  • 两种治疗间多数生活质量差异超过最小临床重要差异。
  • 1年后,肾上腺切除术患者几乎所有生活质量指标恢复正常;药物治疗患者多数指标改善但未全部达到一般人群水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In primary aldosteronism (PA), two subtypes are distinguished: aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH). In general, these are treated by adrenalectomy (ADX) and mineralocorticoid receptor antagonists (MRA), respectively. OBJECTIVE: To compare the effects of surgical treatment and medical treatment on quality of life (QoL). DESIGN: Post hoc comparative effectiveness study within the Subtyping Primary Aldosteronism: A Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan (SPARTACUS) trial. SETTING: Twelve Dutch hospitals and one Polish hospital. PARTICIPANTS: Patients with PA (n = 184). INTERVENTIONS: ADX or MRAs. MAIN OUTCOME MEASURES: At baseline and 6-month and 1-year follow-up, we assessed QoL by two validated questionnaires: RAND 36-Item Health Survey 1.0 (RAND SF-36) and European Quality of Life-5 Dimensions (EQ-5D). RESULTS: At baseline, seven of eight RAND SF-36 subscales and both summary scores, as well as three of five EQ-5D dimensions and the visual analog scale, were lower in patients with PA compared with the general population, especially in women. The beneficial effects of ADX were larger than for MRAs for seven RAND SF-36 subscales, both summary scores, and health change. For the EQ-5D, we detected a difference in favor of ADX in two dimensions and the visual analog scale. Most differences in QoL between both treatments exceeded the minimally clinically important difference. After 1 year, almost all QoL measures had normalized for adrenalectomized patients. For patients on medical treatment, most QoL measures had improved but not all to the level of the general population. CONCLUSION: Both treatments improve QoL in PA, underscoring the importance of identifying these patients. QoL improved more after ADX for suspected APA than after initiation of medical treatment for suspected BAH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Velema M, Dekkers T, Hermus A, et al. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab. 2018. PMID: 29099925. doi:10.1210/jc.2017-01442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。